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Expertise in Allergy and Immunology Can Aid Other
Medical Specialties
S. Gunnar O. Johansson, MD, PhD
Allergy has come a long way as a medical science sincethe discovery of Immunoglobulin E (IgE) some 40
years ago. We have become much more proficient in
diagnosing and managing classic allergic conditions like
asthma, rhinitis, and eczema. However, I am also con-
vinced that allergists and immunologists can make valu-
able contributions to other medical specialties.
A case in point is anesthesiology. Anaphylaxis during
general anesthesia is recognized as a severe problem and a
threat to patient safety. Neuromuscular blocking agents
(NMBAs) represent the most frequent cause, with suxam-
ethonium (SUX) as the substance most often involved. Other
agents are latex, dextran, and various drugs.1
Together with my friend and colleague Erik Florvaag
at Haukeland University Hospital in Bergen, Norway, and
my coworkers at the Department of Medicine, Clinical
Immunology and Allergy at the Karolinska Institute in
Stockholm, I have recently had the satisfaction of bringing
new light on this issue. Our findings have had considerable
clinical and health economic effects. Through prevention,
a sharp decline in IgE sensitization to NMBAs and also
cases of anaphylaxis during general anesthesia is seen and
is presently under investigation in Norway, a former high-
prevalence country.
The starting point for our investigations was an
intriguing discrepancy found in the frequency of such
reactions in Norway and Sweden, 2 countries geographi-
cally and socially closely related. Clinical reports showed
that anaphylactic reactions to NMBAs were on the order of
10 times higher in Norway than in Sweden. Because the
patient must already be IgE-sensitized to react upon expo-
sure to the NMBA, could there be an unknown, environ-
mental exposure factor?
To look for such a factor, we undertook an environ-
mental exposure study, involving 84 household and other
environmental chemicals—skin care ointments, hair care
products, cough syrups, lozenges, toothpastes, cleansers,
and motor oils—which were collected from the homes of
individuals in Bergen and Stockholm, persons that had
proven to be sensitized to SUX and nonsensitized persons.
We could find no differences in exposure between persons
from Sweden and those from Norway, with one crucial
exception: In Norway, but not in Sweden, a cough mixture,
Tuxi, (Weifa AS, Oslo, Norway), was used that contained
pholcodine (PHO), which in principle is a modified mor-
phine (MOR).
To explore the possible effects of this difference in
exposure, we decided to perform a comparative study to
document the prevalence of IgE sensitization to PHO in the
2 countries. As morphine has been suggested as being
suitable for the screening of individuals sensitized to the
quaternary ammonium ion epitope, the most likely aller-
genic epitope for the specific binding of IgE to the NMBA,
we also tested for sensitization to MOR. The results
showed that in Norway 0.4% of persons who donated
blood, 3.7% of patients with allergies, and 38.5% of
patients with an anaphylactic reaction to NMBAs were
sensitized to SUX. The corresponding percentages for
MOR were 5%, 10%, and 66.7%, respectively. Among
those from Stockholm who donated blood and patients
with allergies, none with antibodies to SUX or MOR were
found. IgE antibodies to PHO were found in 6% of persons
who donated blood that were from Bergen but in no one
from Stockholm.2
Thrilled by this discovery, we initiated clinical stud-
ies to compare the effects on IgE production of Tuxi and
PHO-free drugs. A pilot study with individuals IgE-sensi-
tized and nonsensitized showed that PHO exposure caused
an extreme, most unexpected, close to 100-fold increase of
serum levels of IgE and IgE antibodies to PHO, MOR, and
SUX.3 However, only the IgE-sensitized individuals re-
sponded. The origin of the IgE was polyclonal and resem-
bled the IgE response in the graft versus host reaction after
bone marrow transplantation.4 These findings were con-
firmed in a controlled, randomized clinical trial on a
population with previously diagnosed IgE-mediated ana-
phylaxis toward NMBAs.5
As a result of these studies, the Norwegian producer
decided not to renew the marketing license for Tuxi, which
was taken off the market in March 2007. The long-term
immunologic and clinical consequences will take some
time to document, but just a year after the withdrawal, the
percentage of sera that was sent to the Haukeland Univer-
sity Hospital allergy laboratory and found to have IgE
antibodies to PHO, MOR, and SUX was just about half as
much as when Tuxi was on the market. And even more
satisfying, the number of cases of anaphylaxis in connec-
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The Norwegian findings have also prompted studies
in other countries. The fact is that reports of NMBA-
induced anaphylaxis are considerably more common in
countries such as France and the United Kingdom, which
are high consumers of PHO, than in low- or non-consum-
ing countries such as Finland, Germany, and the United
States. An international study on the connection between
PHO consumption and IgE sensitization in 9 different
countries supports the findings in Norway: a high preva-
lence of IgE sensitization to PHO in high-consumption
countries.6 An extension of this study to southeast Asia is
currently in progress where there are many countries, for
example, Australia and New Zealand, known to have
problems with NMBA anaphylaxis usually combined with
high sales of PHO. Withdrawal of PHO-containing drugs
seems most urgent in these high-consuming countries.
It has recently come to my attention that a PHO-
containing drug was also marketed in Sweden back in the
1970s and 1980s. The cough syrup Tussokon (Pharmacia AB,
Uppsala, Sweden) was phased out of the market between
1987 and 1989. To further test the pholcodine hypothesis, we
analyzed some Swedish sera from the 1970s and 1980s found
in our freezers. As many as 5% to 6% of these sera had
antibodies to PHO, whereas only 2% of the sera from the
1990s and none from 2002 or later tested positive for these
antibodies.7
The results of our pholcodine work lend strong support
to the opinion that allergists need to be involved in the
investigation of cases of anaphylaxis in connection with
anesthesia. Cross-disciplinary collaboration can obviously
yield results of great clinical and health economic value.
For me, personally, it feels very satisfying to help avoid
concern and suffering among patients undergoing surgery and
to facilitate the work of surgeons and anesthesiologists.
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